Skip to main content
. 2022 Oct 6;13:982786. doi: 10.3389/fimmu.2022.982786

Figure 6.

Figure 6

Protein kinase R (PKR) activation controls type I IFN response and NF-κB pathway activation in C20 cells following ONX-0914 treatment. C20 cells were subjected to treatment with 200nM ONX-0914 or DMSO control for 24h following pre-treatment with 1µM PKR inhibitor C16 for 2h. (A, B) Western blot analysis of UPR/ISR proteins in C20 cells following treatments. (C, D) Quantitative reverse transcription PCR (RT-PCR) analysis of ATF4 (C) and CHOP (D) mRNA levels in C20 cells following treatments. (E) Western blot analysis of type I IFN response proteins in C20 cells following treatments. (F) Quantitative RT-PCR analysis of IFNβ1 mRNA level in C20 cells following treatments. (G) IFN score calculated by ISG median fold change in C20 cells following treatments. (H) Western blot analysis of NF-κB pathway proteins in C20 cells following treatments. (I) Quantitative reverse transcription PCR (RT-PCR) analysis of NF-κB targets mRNA levels in C20 cells following treatments. All data are given (n=3) by mean ± SEM; *: P < 0.05, **: P < 0.01, ***: P < 0.001.